

PTO/SB/08A (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
		Application Number	10788,606		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	February 27, 2004		
		First Named Inventor	Mary E. Brunkow		
		Art Unit	1844		
		Examiner Name			
Sheet	1	of	2	Attorney Docket Number	60117-109

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
XZ		US-5,837,458	11-17-1998		
XZ		US-5,830,721	11-03-1998		
XZ		US-5,811,238	09-22-1998		
XZ		US-5,780,263	07-14-1998		
XZ		US-5,453,492	09-26-1995		
XZ		US-4,376,110	03-08-1983		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
XZ		WO-92/06693	04-30-1992			
XZ		WO-91/13152	09-05-1991			


Examiner Signature		Date Considered	8/22/2005
-----------------------	--	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1644
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	60117-109

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
XZ		BONALDO ET AL., <i>Accession No. A1113131</i> , EMBL SEQUENCE DATABASE, 1998.	
XZ		HSU ET AL., <i>The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities</i> , MOLECULAR CELL, 1:673-683, 1998.	
XZ		IEMURA ET AL., <i>Direct Binding of Follistatin to a Complex of Bone-Morphogenetic Protein and its Receptor Inhibits Ventral and Epidermal Cell Fates in Early Xenopus Embryo</i> , PROC. NATL. ACAD. SCI. USA, 95:9337-9342, 1998.	
XZ		BIRREN ET AL., <i>Accession No. AC003098</i> , EMBL SEQUENCE DATABASE, 1997.	
XZ		HILLER ET AL., <i>Accession No. AA393939</i> , EMBL SEQUENCE DATABASE, 1997.	
XZ		HILLER ET AL., <i>Accession No. AA393768</i> , EMBL SEQUENCE DATABASE, 1997.	
XZ		BONALDO ET AL., <i>Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery</i> , GENOME RES., 6(9):791, 1996.	
XZ		FUJIWARA ET AL., <i>Accession No. D79813</i> , EMBL SEQUENCE DATABASE, 1996.	
XZ		KHOSLA ET AL., <i>Concise Review for Primary-Care Physicians. Treatment Options for Osteoporosis</i> , MAYO CLIN PRO, 70:978-982, 1995.	
XZ		HAY ET AL., <i>ATCC CELL LINES AND HYBRIDOMAS</i> , 8TH ED., 149, 258 AND 428, 1994.	
XZ		RIGGS, <i>Overview of Osteoporosis</i> , WEST J. MED., 154:63-77, 1991.	
XZ		HARLOW ET AL., <i>ANTIBODIES: A LABORATORY MANUAL</i> , COLD SPRING HARBOR LABORATORY, COLD SPRING HARBOR, NY, 141-157, 1988.	

Examiner Signature		Date Considered	8/22/2005
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



(Use as many sheets as necessary)

Sheet 1

1

of

4

Application Number	10/788,608
Filing Date	February 27, 2004
First Named Inventor	Mary E. Brunkow
Art Unit	1644
Examiner Name	Patrick Nolan
Attorney Docket Number	60117-109

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
XZ	AA	6,395,511	05-28-2002	Brunkow et al.	
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
XZ	AQ	WO 02/24888 A2	03-28-2002	GENENTECH, INC.		
	AR					
	AS					
	AT					
	AU					
	AV					

Joseph Li

Date _____

Considered


8/22/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours total to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/788.606
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1644
				Examiner Name	Patrick Nolan
Sheet	2	of	4	Attorney Docket Number	60117-109

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
XZ	BA	Genbank Accession No. AAB33865, May 27, 1995.	
XZ	BB	Genbank Accession No. CAA88759, January 8, 1997.	
XZ	BC	Genbank Accession No. U25110, February 2, 1996.	
XZ	BD	Genbank Accession No. Z48923, January 8, 1997.	
XZ	BE	BENDAYAN, M., "Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody," J. Histochem. Cytochem. (1995) 43(9): 881-886.	
XZ	BF	BOST ET AL., "Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2," Immunol. Invest. (1988) 17(6&7):577-586.	
XZ	BG	BRUNKOW ET AL., "Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cysteine Knot-Containing Protein." Am. J. Hum. Genet. (2001) 68:577-589.	
XZ	BH	CAMPBELL ET AL., "Totipotency or Multipotentiality of Cultured Cells: Applications and Progress," Theriogenology (1997) 47:63-72.	
XZ	BI	COLMAN, P., "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions," Research in Immunology (1994) 145:33-36.	

Examiner Signature		Date Considered	8/22/2005
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/788.606		
		Filing Date	February 27, 2004		
		First Named Inventor	Mary E. Brunkow		
		Art Unit	1644		
		Examiner Name	Patrick Nolan		
Sheet	3	of	4	Attorney Docket Number	60117-109

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
XZ	CA	DURHAM ET AL., "Alterations in Insulin-Like Growth Factor (IGF)-Dependent IGF-Binding Protein-4 Proteolysis in Transformed Osteoblastic Cells" Endocrinology (1995) 136(4):1374-1380.	
XZ	CB	HOFFMAN ET AL., "BMP Signaling Pathways in Cartilage and Bone Formation," Critical Review in Eukaryotic Gene Expression (2001) 11(1-3):23-45.	
XZ	CC	LIAN ET AL., "Bone Formation: Osteoblast Lineage Cells, Growth Factors, Matrix Proteins, and the Mineralization Process," Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4 th Edition (1999) 14-29.	
XZ	CD	MULLINS ET AL., "Perspectives Series: Molecular Medicine in Genetically Engineered Animals; Transgenesis in the Rat and Larger Mammals," J. Clin. Invest. (1996) 97(7):1557-1560	
XZ	CE	NICOLAS ET AL., "An Age-Related Decrease in the Concentration of Insulin-Like Growth Factor Binding Protein-5 in Human Cortical Bone," Calcif. Tissue Int. (1995) 57:206-212	
XZ	CF	OSHIMA ET AL., "TGF- β Receptor Type II Deficiency Results in Defects of Yolk Sac Hematopoiesis and Vasculogenesis," Developmental Biology (1996) 179:297-302.	
XZ	CG	PITTENGER ET AL., "Multilineage Potential of Adult Human Mesenchymal Stem Cells," Science (1999) 284:143-147.	
XZ	CH	POCKWINSE ET AL., "Expression of Cell Growth and Bone Specific Genes at Single Cell Resolution During Development of Bone Tissue-Like Organization in Primary Osteoblast Cultures," Journal of Cellular Biochemistry (1992) 49:310-323.	
XZ	CI	SALI ET AL., "Comparative Protein Modelling by Satisfaction of Spatial Restraints," J. Mol. Biol. (1993) 234:779-815.	

Examiner Signature		Date Considered	8/22/2005
--------------------	---	-----------------	-----------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/788.606
		Filing Date	February 27, 2004
		First Named Inventor	Mary E. Brunkow
		Art Unit	1644
		Examiner Name	Patrick Nolan
Sheet	4	of	4
		Attorney Docket Number	60117-109

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
XZ	DA	SCHMITT ET AL., "Bone Morphogenetic Proteins: An Update on Basic Biology and Clinical Relevance," Journal of Orthopaedic Research (1999) 17:269-278.	
XZ	DB	SCHLUNEGGER ET AL., "Refined Crystal Structure of Human Transforming Growth Factor $\beta 2$ at 1.95 Å Resolution," J. Mol. Biol. (1993) 231:445-458.	
XZ	DC	SERRA ET AL., "Expression of a Truncated, Kinase-Defective TGF- β Type II Receptor in Mouse Skeletal Tissue Promotes Terminal Chondrocyte Differentiation and Osteoarthritis," J Cell Biol. (1997) 139(2):541-552.	
XZ	DD	SMITH, "TGF β Inhibitors, New and Unexpected Requirements in Vertebrate Development," TIG (1999) 15(1):3-5.	
XZ	DE	ZIMMERMAN ET AL., "The Spemann Organizer Signal noggin Binds and Inactivates Bone Morphogenetic Protein 4," Cell (1996) 86:599-606.	
	DG		
	DH		
	DI		

Examiner Signature		Date Considered	8/22/2005
--------------------	---	-----------------	-----------